Nature

Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy

γδT cell biology in cancer has been studied for decades but remains poorly understood mainly due to species differences in preclinical models and a lack of appropriate analytical tools. This lack of ...
Nature

Transitioning from native to synthetic receptors: broadening T-cell engineering and beyond

T cells play a pivotal role in defending against infection and cancer. The highly specific recognition of pathogens and tumor cells is mediated by the T-cell receptor (TCR), which undergoes somatic ...
The American Journal of Managed Care

Study Identifies Key Predictors of Successful CD3+ Cell Apheresis for CAR T Manufacturing in DLBCL

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
Monthly Prescribing Reference

GPRC5D-Targeting Bispecific Antibody Gets Orphan Drug Status for Multiple Myeloma

LBL-034 is an investigational GPRC5D-targeted CD3 bispecific antibody. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LBL-034 for the treatment of multiple myeloma.
BioWorld

Cytospire raises £61M series A to target EGFR in solid tumors

Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance the lead program CYT-X300 to the ...